This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Sandbox Reserved 1474
From Proteopedia
(Difference between revisions)
| Line 53: | Line 53: | ||
<ref name="Immunotherapy for the treatment of drug abuse">DOI: 10.1016/j.pharmthera.2005.06.009</ref> | <ref name="Immunotherapy for the treatment of drug abuse">DOI: 10.1016/j.pharmthera.2005.06.009</ref> | ||
<ref name="quantitative determination of total methamphetamine and active metabolites in Rat tissue by liquid chromatography with tandem mass spectrometric detection">PMID: 17233534 </ref> | <ref name="quantitative determination of total methamphetamine and active metabolites in Rat tissue by liquid chromatography with tandem mass spectrometric detection">PMID: 17233534 </ref> | ||
| - | <ref name="">PMID: </ref> | + | <ref name="Using Hapten Design to Discover Therapeutic Monoclonal Antibodies for Treating Methamphetamine Abuse">PMID: 17452421</ref> |
| - | <ref name="">PMID: </ref> | + | <ref name="Development and Preclinical Testing of a High-Affinity Single-Chain Antibody against (+)-Methamphetamine">PMID: 18192498 </ref> |
| - | <ref name="">PMID: </ref> | + | <ref name="Development of Active and Passive Human Vaccines to Treat Methamphetamine Addiction">PMID: 19276653 </ref> |
<ref name="">PMID: </ref> | <ref name="">PMID: </ref> | ||
<ref name="">PMID: </ref> | <ref name="">PMID: </ref> | ||
Revision as of 06:44, 8 December 2018
Contents |
Immunotherapy for treating Methamphetamine Abuse
Introduction
Two major approaches to developing drug-specific immunotherapies: active and passive immunization
Antibody pharmacokinetics, pharmacodynamics and metabolism of therapeutic and diagnostic antibodies
Generation of anti-(+)methamphetamine antibodies during active immunization of rats
Function
Disease
Relevance
Structural highlights
Aromatic-Aromatic Interaction: A Mechanism of Protein Structure Stabilization
| |||||||||
| scFv6H4 in complex with amphetamine | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Ligands: | , | ||||||||
| Gene: | IgG (LK3 transgenic mice) | ||||||||
| Activity: | , | ||||||||
| Related: | 3gkz, 4laq, 4las | ||||||||
| |||||||||
| Resources: | FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT | ||||||||
| Coordinates: | save as pdb, mmCIF, xml | ||||||||
This is a sample scene created with SAT to by Group, and another to make of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.
</StructureSection>
References
[1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [10] [10] [10] [10] [10] [10] PMID:
- ↑ Burley SK, Petsko GA. Aromatic-aromatic interaction: a mechanism of protein structure stabilization. Science. 1985 Jul 5;229(4708):23-8. PMID:3892686
- ↑ doi: https://dx.doi.org/10.1016/S1567-5769(00)00019-9
- ↑ Peterson EC, Owens SM. Designing immunotherapies to thwart drug abuse. Mol Interv. 2009 Jun;9(3):119-24. doi: 10.1124/mi.9.3.5. PMID:19592672 doi:http://dx.doi.org/10.1124/mi.9.3.5
- ↑ Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004 Nov;93(11):2645-68. doi: 10.1002/jps.20178. PMID:15389672 doi:http://dx.doi.org/10.1002/jps.20178
- ↑ Kosten T, Owens SM. Immunotherapy for the treatment of drug abuse. Pharmacol Ther. 2005 Oct;108(1):76-85. doi: 10.1016/j.pharmthera.2005.06.009. PMID:16023218 doi:http://dx.doi.org/10.1016/j.pharmthera.2005.06.009
- ↑ Hendrickson H, Laurenzana E, Owens SM. Quantitative determination of total methamphetamine and active metabolites in rat tissue by liquid chromatography with tandem mass spectrometric detection. AAPS J. 2006 Nov 22;8(4):E709-17. doi: 10.1208/aapsj080480. PMID:17233534 doi:http://dx.doi.org/10.1208/aapsj080480
- ↑ Peterson EC, Gunnell M, Che Y, Goforth RL, Carroll FI, Henry R, Liu H, Owens SM. Using hapten design to discover therapeutic monoclonal antibodies for treating methamphetamine abuse. J Pharmacol Exp Ther. 2007 Jul;322(1):30-9. doi: 10.1124/jpet.106.117150. Epub, 2007 Apr 23. PMID:17452421 doi:http://dx.doi.org/10.1124/jpet.106.117150
- ↑ Peterson EC, Laurenzana EM, Atchley WT, Hendrickson HP, Owens SM. Development and preclinical testing of a high-affinity single-chain antibody against (+)-methamphetamine. J Pharmacol Exp Ther. 2008 Apr;325(1):124-33. doi: 10.1124/jpet.107.134395. Epub , 2008 Jan 11. PMID:18192498 doi:http://dx.doi.org/10.1124/jpet.107.134395
- ↑ Gentry WB, Ruedi-Bettschen D, Owens SM. Development of active and passive human vaccines to treat methamphetamine addiction. Hum Vaccin. 2009 Apr;5(4):206-13. Epub 2009 Apr 20. PMID:19276653
- ↑ 10.0 10.1 10.2 10.3 10.4 10.5 10.6 . PMID:216315890657
